Sheila M. Fleming, Ph.D. - Publications

Arizona State University, Tempe, AZ, United States 
Neurobiology of Chronic Stress

60 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Peng Y, Liou B, Lin Y, Mayhew CN, Fleming SM, Sun Y. iPSC-derived neural precursor cells engineering recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology. Molecular Therapy. Methods & Clinical Development. 29: 185-201. PMID 37063480 DOI: 10.1016/j.omtm.2023.03.007  0.36
2023 Simons E, Fleming SM. Role of rodent models in advancing precision medicine for Parkinson's disease. Handbook of Clinical Neurology. 193: 3-16. PMID 36803818 DOI: 10.1016/B978-0-323-85555-6.00002-3  0.306
2021 Fleming SM, Davis A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Neuropharmacology. 202: 108870. PMID 34742741 DOI: 10.1016/j.neuropharm.2021.108870  0.339
2021 Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, Baldauf L, Fleming S, Masliah E, Chesselet MF, Fanselow MS, Richter F. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Neurobiology of Disease. 158: 105478. PMID 34390837 DOI: 10.1016/j.nbd.2021.105478  0.394
2020 Gezer AO, Kochmanski J, VanOeveren SE, Cole-Strauss A, Kemp CJ, Patterson JR, Miller KM, Kuhn NC, Herman DE, McIntire A, Lipton JW, Luk KC, Fleming SM, Sortwell CE, Bernstein AI. Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits. Neurobiology of Disease. 104947. PMID 32422283 DOI: 10.1016/J.Nbd.2020.104947  0.316
2020 Froula JM, Castellana-Cruz M, Anabtawi NM, Camino JD, Chen SW, Thrasher DR, Freire J, Yazdi AA, Fleming S, Dobson CM, Kumita JR, Cremades N, Volpicelli-Daley LA. Correction: Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice. The Journal of Biological Chemistry. 295: 1142. PMID 31980482 DOI: 10.1074/Jbc.Aac119.012485  0.406
2020 Neal ML, Fleming SM, Budge KM, Boyle AM, Kim C, Alam G, Beier EE, Wu LJ, Richardson JR. Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 34: 1679-1694. PMID 31914683 DOI: 10.1096/Fj.201900567Rr  0.301
2019 Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC, Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM, Kanaan NM, Paumier KL, El-Agnaf OMA, et al. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils. Neurobiology of Disease. 104525. PMID 31276792 DOI: 10.1016/J.Nbd.2019.104525  0.316
2019 Froula JM, Castellana-Cruz M, Anabtawi NM, Camino JD, Chen SW, Thrasher DR, Freire J, Yazdi AA, Fleming S, Dobson CM, Kumita JR, Cremades N, Volpicelli-Daley LA. Defining α-synuclein species responsible for Parkinson disease phenotypes in mice. The Journal of Biological Chemistry. PMID 31142553 DOI: 10.1074/Jbc.Ra119.007743  0.338
2018 Colter BT, Garber HF, Fleming SM, Fowler JP, Harding GD, Hooven MK, Howes AA, Infante SK, Lang AL, MacDougall MC, Stegman M, Taylor KR, Curran CP. Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls. Neurotoxicology. PMID 29409959 DOI: 10.1016/J.Neuro.2018.01.008  0.385
2018 Dirr ER, Ekhator OR, Blackwood R, Holden JG, Masliah E, Schultheis PJ, Fleming SM. Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein. Behavioural Brain Research. 343: 41-49. PMID 29407413 DOI: 10.1016/J.Bbr.2018.01.029  0.325
2017 Fleming SM. Mechanisms of Gene-Environment Interactions in Parkinson's Disease. Current Environmental Health Reports. PMID 28417442 DOI: 10.1007/s40572-017-0143-2  0.307
2015 Grant LM, Kelm-Nelson CA, Hilby BL, Blue KV, Paul Rajamanickam ES, Pultorak JD, Fleming SM, Ciucci MR. Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's disease. Journal of Neuroscience Research. PMID 26234713 DOI: 10.1002/Jnr.23625  0.4
2015 Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiology of Disease. 82: 185-199. PMID 26093169 DOI: 10.1016/J.Nbd.2015.06.003  0.37
2014 Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacology Research & Perspectives. 2: e00065. PMID 25505609 DOI: 10.1002/Prp2.65  0.432
2014 Fleming SM, Espay AJ. Cinnamon in a mouse model of PD: Khasnavis S, Pahan K. Cinnamon protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol 2014;9:569-581. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1466. PMID 25284437 DOI: 10.1002/Mds.26034  0.453
2014 Lehmkuhl AM, Dirr ER, Fleming SM. Olfactory assays for mouse models of neurodegenerative disease. Journal of Visualized Experiments : Jove. e51804. PMID 25177842 DOI: 10.3791/51804  0.371
2014 Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, Zhu C, Mortazavi F, Mulligan CK, Sioshansi PC, Hean S, De La Rosa K, Khanna R, Flanagan J, Lockhart DJ, et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 840-56. PMID 25037721 DOI: 10.1007/S13311-014-0294-X  0.454
2014 Fleming SM, Espay AJ. Ribosomal s15: A novel therapeutic target for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 990. PMID 24865568 DOI: 10.1002/Mds.25932  0.344
2014 Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, Mulligan CK, Sioshansi PC, Zhu C, Coppola G, Bordet T, et al. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiology of Disease. 69: 263-75. PMID 24844147 DOI: 10.1016/J.Nbd.2014.05.012  0.503
2014 Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE. Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. Gene Therapy. 21: 682-93. PMID 24807806 DOI: 10.1038/Gt.2014.42  0.349
2013 Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. Plos One. 8: e81426. PMID 24312298 DOI: 10.1371/Journal.Pone.0081426  0.403
2013 Fleming SM, Jordan MC, Mulligan CK, Masliah E, Holden JG, Millard RW, Chesselet MF, Roos KP. Impaired baroreflex function in mice overexpressing alpha-synuclein. Frontiers in Neurology. 4: 103. PMID 23888153 DOI: 10.3389/Fneur.2013.00103  0.439
2013 Fleming SM, Ekhator OR, Ghisays V. Assessment of sensorimotor function in mouse models of Parkinson's disease. Journal of Visualized Experiments : Jove. PMID 23851663 DOI: 10.3791/50303  0.444
2013 Schultheis PJ, Fleming SM, Clippinger AK, Lewis J, Tsunemi T, Giasson B, Dickson DW, Mazzulli JR, Bardgett ME, Haik KL, Ekhator O, Chava AK, Howard J, Gannon M, Hoffman E, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics. 22: 2067-82. PMID 23393156 DOI: 10.1093/Hmg/Ddt057  0.514
2013 Chesselet MF, Richter F, Gao F, Fleming SM, Michaud M, Zhu C, Coppola G, Bordet T, Pruss R. Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson's Disease Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 128. DOI: 10.1016/B978-0-12-800044-1.00112-4  0.336
2012 Fleming SM, Schallert T, Ciucci MR. Cranial and related sensorimotor impairments in rodent models of Parkinson's disease. Behavioural Brain Research. 231: 317-22. PMID 22394540 DOI: 10.1016/J.Bbr.2012.02.034  0.466
2012 Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, Jentsch JD, Chesselet MF. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. The European Journal of Neuroscience. 35: 870-82. PMID 22356593 DOI: 10.1111/J.1460-9568.2012.08012.X  0.46
2012 Glajch KE, Fleming SM, Surmeier DJ, Osten P. Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease. Behavioural Brain Research. 230: 309-16. PMID 22178078 DOI: 10.1016/J.Bbr.2011.12.007  0.456
2011 Fleming SM. Cardiovascular autonomic dysfunction in animal models of Parkinson's disease. Journal of Parkinson's Disease. 1: 321-7. PMID 23933655 DOI: 10.3233/Jpd-2011-11042  0.417
2011 Cabeza-Arvelaiz Y, Fleming SM, Richter F, Masliah E, Chesselet MF, Schiestl RH. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Molecular Neurodegeneration. 6: 83. PMID 22165993 DOI: 10.1186/1750-1326-6-83  0.483
2011 Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences. 46: 597-606. PMID 21193046 DOI: 10.1016/J.Mcn.2010.12.011  0.493
2011 Chan CS, Glajch KE, Gertler TS, Guzman JN, Mercer JN, Lewis AS, Goldberg AB, Tkatch T, Shigemoto R, Fleming SM, Chetkovich DM, Osten P, Kita H, Surmeier DJ. HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. Nature Neuroscience. 14: 85-92. PMID 21076425 DOI: 10.1038/Nn.2692  0.417
2010 Goebel M, Fleming SM, Million M, Stengel A, Taché Y, Wang L. Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctions. Neuroscience Letters. 473: 11-5. PMID 20132869 DOI: 10.1016/J.Neulet.2010.01.068  0.351
2010 Schallert T, Fleming SM. Dopamine and Motor Function in Rat and Mouse Models of Parkinson's Disease Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0019  0.32
2009 Fleming SM. Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders. International Review of Neurobiology. 89: 57-65. PMID 19900615 DOI: 10.1016/S0074-7742(09)89003-X  0.391
2009 Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proceedings of the National Academy of Sciences of the United States of America. 106: 11125-30. PMID 19549824 DOI: 10.1073/Pnas.0811753106  0.302
2009 Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 1962-76. PMID 19228951 DOI: 10.1523/Jneurosci.5351-08.2009  0.478
2009 Meurers BH, Zhu C, Fernagut PO, Richter F, Hsia YC, Fleming SM, Oh M, Elashoff D, Dicarlo CD, Seaman RL, Chesselet MF. Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. Neurobiology of Disease. 33: 182-92. PMID 19013527 DOI: 10.1016/J.Nbd.2008.10.001  0.357
2009 Chesselet M, Fleming S, Richter F, Frias C, Mortazavi F, Maidment N, Levine M. O.026 Mice over-expressing wild-type human alpha-synuclein as tools for therapeutic discovery in Parkinson's disease Parkinsonism & Related Disorders. 15: S8. DOI: 10.1016/S1353-8020(09)70041-0  0.415
2009 Fleming SM, Wang L, Jordan MC, Roos KP, Masliah E, Taché Y, Chesselet M-. S9.3 Autonomic dysfunction in mice overexpressing human wildtype alpha synuclein Autonomic Neuroscience: Basic and Clinical. 149: 37-38. DOI: 10.1016/J.Autneu.2009.05.048  0.38
2008 Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. The European Journal of Neuroscience. 28: 247-56. PMID 18702696 DOI: 10.1111/J.1460-9568.2008.06346.X  0.443
2008 Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism & Related Disorders. 14: S84-7. PMID 18585084 DOI: 10.1016/J.Parkreldis.2008.04.004  0.499
2008 Wang L, Fleming SM, Chesselet MF, Taché Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport. 19: 873-6. PMID 18463504 DOI: 10.1097/Wnr.0B013E3282Ffda5E  0.431
2008 Reliene R, Fleming SM, Chesselet MF, Schiestl RH. Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 46: 1371-7. PMID 18037553 DOI: 10.1016/J.Fct.2007.08.028  0.356
2007 Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, Chesselet MF. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (New York, N.Y.). 61: 991-1001. PMID 17879265 DOI: 10.1002/Syn.20456  0.482
2006 Fleming SM, Chesselet MF. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behavioural Pharmacology. 17: 383-91. PMID 16940759 DOI: 10.1097/00008877-200609000-00004  0.47
2006 Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience. 142: 1245-53. PMID 16934409 DOI: 10.1016/J.Neuroscience.2006.07.005  0.452
2005 Fleming SM, Fernagut PO, Chesselet MF. Genetic mouse models of parkinsonism: strengths and limitations. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 495-503. PMID 16389313 DOI: 10.1602/Neurorx.2.3.495  0.443
2005 Castañeda E, Fleming S, Paquette MA, Boat K, Moffett J, Stachowiak EK, Bloom DC, Stachowiak MK. Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate. Physiology & Behavior. 84: 525-35. PMID 15811387 DOI: 10.1016/J.Physbeh.2005.01.019  0.323
2005 Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, Chesselet MF, Kim KS. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2132-7. PMID 15728853 DOI: 10.1523/Jneurosci.3718-04.2005  0.517
2005 Fleming SM, Delville Y, Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behavioural Brain Research. 156: 201-13. PMID 15582106 DOI: 10.1016/J.Bbr.2004.05.024  0.471
2005 Chesselet MF, Fernagut PO, Fleming S. Parkinson's disease models: From toxins to genes Drug Discovery Today: Disease Models. 2: 299-303. DOI: 10.1016/J.Ddmod.2005.11.008  0.441
2004 Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 9434-40. PMID 15496679 DOI: 10.1523/Jneurosci.3080-04.2004  0.451
2004 Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends in Neurosciences. 27: 691-7. PMID 15474170 DOI: 10.1016/J.Tins.2004.08.008  0.401
2004 Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. The Journal of Comparative Neurology. 478: 418-26. PMID 15384065 DOI: 10.1002/Cne.20305  0.376
2004 Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Experimental Neurology. 187: 418-29. PMID 15144868 DOI: 10.1016/J.Expneurol.2004.01.023  0.381
2003 Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. The Journal of Biological Chemistry. 278: 43628-35. PMID 12930822 DOI: 10.1074/Jbc.M308947200  0.504
2003 Schallert T, Woodlee MT, Fleming SM. Experimental focal ischemic injury: behavior-brain interactions and issues of animal handling and housing. Ilar Journal / National Research Council, Institute of Laboratory Animal Resources. 44: 130-43. PMID 12652008 DOI: 10.1093/Ilar.44.2.130  0.308
2003 Schallert T, Fleming SM, Woodlee MT. Should the injured and intact hemispheres be treated differently during the early phases of physical restorative therapy in experimental stroke or parkinsonism? Physical Medicine and Rehabilitation Clinics of North America. 14: S27-46. PMID 12625636 DOI: 10.1016/S1047-9651(02)00055-4  0.315
Show low-probability matches.